Psychedelic treatments for trauma-related disorders

Chula Launches the Latest Parkinson's Gloves to Reduce Tremors

Retrieved on: 
Thursday, November 2, 2023
Tremor, Improvement Science Research Network, Ageing, Faculty, PD, Patent, Innovation, Public, Government, Parkinson's disease, Family, King Chulalongkorn Memorial Hospital, Psychedelic treatments for trauma-related disorders, Private, Disease, Organization, Ministry, Private sector, Quality of life, Ministry of Higher Education (Syria), Sulfotransferase, Injury, Risk, Speed, Imperial College Faculty of Medicine, Hand, Patient, Motion, Chulalongkorn University, Memory, Pharmaceutical industry, Medical device, Health insurance, Personal protective equipment, Research, Science, Environment, Medicine

The current method of treating Parkinson's is taking a cocktail of medications, which is mostly unable to reduce all the tremors.

Key Points: 
  • The current method of treating Parkinson's is taking a cocktail of medications, which is mostly unable to reduce all the tremors.
  • "The tremor-reducing Parkinson's gloves are the first medical device that can help reduce tremors in the hands of PD patients through automatic electric stimulation of the hand muscles.
  • We hope this will help reduce the tremors for the patients without having to increase the dosage of their medication unnecessarily and reduce the risk of brain surgery," discussed Asst.
  • The gloves can be used to reduce tremors in the hand from other conditions as well.

Chula Launches the Latest Parkinson's Gloves to Reduce Tremors

Retrieved on: 
Thursday, November 2, 2023
Tremor, Improvement Science Research Network, Ageing, Faculty, PD, Patent, Innovation, Public, Government, Parkinson's disease, Family, King Chulalongkorn Memorial Hospital, Psychedelic treatments for trauma-related disorders, Private, Disease, Organization, Ministry, Private sector, Quality of life, Ministry of Higher Education (Syria), Sulfotransferase, Injury, Risk, Speed, Imperial College Faculty of Medicine, Hand, Patient, Motion, Chulalongkorn University, Memory, Pharmaceutical industry, Medical device, Health insurance, Personal protective equipment, Research, Science, Environment, Medicine

The current method of treating Parkinson's is taking a cocktail of medications, which is mostly unable to reduce all the tremors.

Key Points: 
  • The current method of treating Parkinson's is taking a cocktail of medications, which is mostly unable to reduce all the tremors.
  • "The tremor-reducing Parkinson's gloves are the first medical device that can help reduce tremors in the hands of PD patients through automatic electric stimulation of the hand muscles.
  • We hope this will help reduce the tremors for the patients without having to increase the dosage of their medication unnecessarily and reduce the risk of brain surgery," discussed Asst.
  • The gloves can be used to reduce tremors in the hand from other conditions as well.

New data validates an association between trauma-related disorders and the development of Parkinson's disease in military veterans

Retrieved on: 
Sunday, August 27, 2023
Movement Disorders (journal), Psychedelic treatments for trauma-related disorders, University, PD, DSM-IV codes, OR, Injury, Research, TBI, Risk, Movement disorder, Odds ratio, Parkinson's disease, Post-traumatic stress disorder, Traumatic brain injury, University of British Columbia, Diagnosis, White, PTSD, Disease, Meat

COPENHAGEN, Denmark, Aug. 27, 2023 /PRNewswire-PRWeb/ -- In a study of nearly 360,000 military veteran records released earlier this year in the Movement Disorders journal, researchers provide evidence that traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD), both trauma-related disorders, are risk factors for Parkinson's disease (PD).

Key Points: 
  • While this correlation has long been suspected, the results of this study validate the hypothesis with the researchers' case-controlled approach and consideration of comorbidities.
  • This study further suggests that these common war-related illnesses may ignite biochemical changes that precede and fuel the development of Parkinson's disease decades later.
  • They furthermore restricted the definition of TBI and PTSD to events that occurred during active military service.
  • The findings thus have important implications for understanding the pathogenesis of PD and for the consideration of novel preventative and disease modifying approaches."

Veterans Exploring Treatment Solutions (VETS) Co-founders Joined Rep. Dan Crenshaw (TX-02) for Press Conference Supporting Bipartisan Legislation Funding Psychedelics Research for Military Service Members

Retrieved on: 
Thursday, June 15, 2023
Psychedelic treatments for trauma-related disorders, Depression, NY-14, Suicide, Newborn Screening Saves Lives Act of 2007, Veteran, Research, Ibogaine, TBI, Silver Star, Moral injury, MDMA, SAN, Navy, PTSD, Pharmaceutical industry, Veterinary medicine

SAN DIEGO, June 15, 2023 /PRNewswire/ -- Veterans Exploring Treatment Solutions (VETS), a nonprofit organization focused on ENDING veteran suicide through psychedelic-assisted therapy, co-founders Marcus and Amber Capone joined Rep. Dan Crenshaw (TX-02) for a press conference on the bipartisan bill proposing funding for psychedelic research for military service members.

Key Points: 
  • SAN DIEGO, June 15, 2023 /PRNewswire/ -- Veterans Exploring Treatment Solutions (VETS), a nonprofit organization focused on ENDING veteran suicide through psychedelic-assisted therapy, co-founders Marcus and Amber Capone joined Rep. Dan Crenshaw (TX-02) for a press conference on the bipartisan bill proposing funding for psychedelic research for military service members.
  • The bill would create a $75 million federal grant program to support research into the therapeutic potential of psychedelics in aiding military servicemembers with qualifying health conditions.
  • As a nonprofit organization that supports veterans in accessing psychedelic-assisted therapies, VETS recognizes the critical importance of psychedelic research in evaluating all viable treatments for military service members, including active duty service members.
  • The trial substances presented in this bill—psilocybin, ibogaine, MDMA, and 5–MeO–DMT—have already shown incredible promise in research for trauma-related disorders.

Dr. Newton Howard Joins Futures Recovery Healthcare Hero's Ascent Advisory Board

Retrieved on: 
Thursday, May 11, 2023
Newton, Substance Abuse, Depression, Report, University, Post-traumatic stress disorder, KIWI, Suicide, Anxiety, Ascent, Hero, Curriculum, Clinical trial, DSM-IV codes, Hero's, Substance Abuse and Mental Health Services Administration, Hope, PTSD, Nuffield Department of Population Health, Research, Brain, Medicine, Psychedelic treatments for trauma-related disorders, Privacy, Veteran, Bangladesh Technical Education Board, Military personnel, Surgery, Death, Alzheimer's disease, Professor, Parkinson's disease, Kinetic, Neurology, Knowledge, Mental health service, IED, Trauma, Mental health, John Radcliffe Hospital, Nursing, Medical device

JUPITER, Fla., May 11, 2023 /PRNewswire/ -- Futures Recovery Healthcare is privileged to welcome Dr. Newton Howard to its Hero's Ascent Advisory Board which helps meet the intense behavioral healthcare needs of first responders, active military members, and veterans.

Key Points: 
  • JUPITER, Fla., May 11, 2023 /PRNewswire/ -- Futures Recovery Healthcare is privileged to welcome Dr. Newton Howard to its Hero's Ascent Advisory Board which helps meet the intense behavioral healthcare needs of first responders, active military members, and veterans.
  • Futures Recovery Healthcare Hero's Ascent makes specialized mental health, substance use disorder, and trauma treatment services accessible to first responders, military personnel, veterans, and their family members.
  • Futures Recovery Healthcare assembled the Hero's Ascent Advisory Board to make its Hero's Ascent offering as effective and relevant as possible.
  • As a Hero's Ascent Advisory Board member, Dr. Howard's work and relatability will profoundly impact first responders and families.

Survivor Winner Donates $100,000 to Veterans Exploring Treatment Solutions (VETS)

Retrieved on: 
Tuesday, April 25, 2023
Psilocybin, Gabler, United States Army Special Forces, Human, Psychedelic treatments for trauma-related disorders, Army, Suicide, Green beret, Veteran, Research, Ibogaine, TBI, Organization, Risk, SAN, Traumatic brain injury, Entrepreneurship, Mental health, Social media, PTSD, Pharmaceutical industry, Veterinary medicine

SAN DIEGO, April 25, 2023 /PRNewswire/ -- Survivor season 43 winner Mike Gabler has donated $100,000 of his $1 million prize winnings to Veterans Exploring Treatment Solutions (VETS), a non-profit providing resources, research, and advocacy for U.S. special operations military veterans seeking mental health treatment with psychedelic-assisted therapies.

Key Points: 
  • SAN DIEGO, April 25, 2023 /PRNewswire/ -- Survivor season 43 winner Mike Gabler has donated $100,000 of his $1 million prize winnings to Veterans Exploring Treatment Solutions (VETS), a non-profit providing resources, research, and advocacy for U.S. special operations military veterans seeking mental health treatment with psychedelic-assisted therapies.
  • As a nonprofit organization that supports veterans in accessing psychedelic-assisted therapies, VETS recognizes the critical importance of psychedelic research.
  • Recent Phase 3 trials of MDMA-assisted therapy for PTSD are demonstrating the significant impact of psychedelic treatment on individuals suffering from trauma-related disorders.
  • Gabler's donation will directly support VETS' work to provide resources, research, and advocacy for veterans seeking psychedelic-assisted therapies.

Veterans Exploring Treatment Solutions (VETS) Applauds Bipartisan Push to Include Active Duty Military Members in Psychedelic-Assisted Therapy Research

Retrieved on: 
Thursday, April 13, 2023
Psilocybin, Letter, Psychedelic treatments for trauma-related disorders, Depression, Suicide, Woman, Research, Ibogaine, TBI, Psychedelic drug, Bangladesh Technical Education Board, Moral injury, SAN, Hand, Mental health, Bipartisanship, NIH, Social media, PTSD, Crenshaw, Pharmaceutical industry, Veteran

As a nonprofit organization that supports veterans in accessing psychedelic-assisted therapies, VETS recognizes the critical importance of including active duty servicemembers in psychedelic research.

Key Points: 
  • As a nonprofit organization that supports veterans in accessing psychedelic-assisted therapies, VETS recognizes the critical importance of including active duty servicemembers in psychedelic research.
  • The recent Phase 3 Trial of MDMA-Assisted Therapy for PTSD demonstrated the significant impact of psychedelic treatment on individuals suffering from trauma-related disorders.
  • Other compounds, like psilocybin and ibogaine, are also showing incredible promise in addressing these issues– but more research is critically needed.
  • Our active duty service men and women deserve to be included in NIH-funded psychedelic research.

Science-Forward Skincare Brand A.P. CHEM® Debuts New Age-Decelerating Products and Stigma-Breaking Social Campaign

Retrieved on: 
Tuesday, April 11, 2023
Mental Health, Millennials, Philanthropy, Alternative Medicine, Consumer, Health, Cosmetics, Generation X, Foundation, Retail, Psychedelic treatments for trauma-related disorders, GABA, Interior design, Autoimmunity, Gen, Inflammation, Hairdresser, Overalls, PTSD, CHEM, Multimedia, Classic, Veteran, Psychedelic drug, Judgement, Ketamine, Xennials, Collection, Serum, Diagnosis, Entrepreneurship, Mental health, Skin, Pharmaceutical industry

CHEM announces the launch of their newest age-decelerating skincare aimed at the Xennial and Gen X community that is both results-driven and accessibly priced.

Key Points: 
  • CHEM announces the launch of their newest age-decelerating skincare aimed at the Xennial and Gen X community that is both results-driven and accessibly priced.
  • CHEM combines the best of classic ingredients with clinically-proven Alt-Pharma™ ingredients to create a power-packed regimen.
  • “Our brand ethos is unique in its advocacy for Psychedelic Medicine because of my personal experience and connection to the cause.
  • CHEM and the “We See You” campaign, please visit www.apchembeauty.com and follow on Instagram at @apchembeauty .